Manufacturer of Controlled Substances; Notice of Registration, 36484 [E7-12942]
Download as PDF
<![CDATA[
36484
Federal Register / Vol. 72, No. 127 / Tuesday, July 3, 2007 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated March 19, 2007, and
published in the Federal Register on
March 27, 2007, (72 FR 14297), Stepan
Company, Natural Products Dept., 100
W. Hunter Avenue, Maywood, New
Jersey 07607, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedule II:
Drug
Schedule
Cocaine (9041) .............................
Ecgonine (9180) ...........................
II
II
The company plans to manufacture in
bulk for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Stepan Company to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated Stepan
Company to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12942 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
jlentini on PROD1PC65 with NOTICES
Michael F. Myers, M.D.; Revocation of
Registration
On January 10, 2007, I, the Deputy
Administrator of the Drug Enforcement
Administration, issued an Order to
Show Cause and Immediate Suspension
of Registration to Michael F. Myers,
M.D. (Respondent) of Woodruff, South
VerDate Aug<31>2005
17:57 Jul 02, 2007
Jkt 211001
Carolina. The Order to Show Cause
proposed the revocation of
Respondent’s DEA Certificate of
Registration, BM5526009, as a
practitioner, on the ground that
Respondent’s continued registration
would be inconsistent with the public
interest. Show Cause Order at 1 (citing
21 U.S.C. 824(a)(4)). The Immediate
Suspension was imposed based on my
preliminary finding that Respondent
had ‘‘diverted large quantities of
controlled substances,’’ and that there
was a ‘‘substantial likelihood that [he]
would continue to divert controlled
substances to drug abusers.’’ Id. at 1–2.
I therefore concluded that Respondent’s
‘‘continued registration during the
pendency of these proceedings would
constitute an imminent danger to the
public health and safety.’’ Id.
The Show Cause Order alleged that
Respondent ‘‘frequently grew marijuana
in [his] residence,’’ that he ‘‘regularly
purchased large quantities of
marijuana,’’ that ‘‘he smoked marijuana
throughout the day on a daily basis,’’
and that he ‘‘regularly distributed
marijuana from [his] residence.’’ Id. at 2.
The Show Cause Order further alleged
that Respondent ‘‘regularly exchanged
controlled substance prescriptions for
marijuana and other prescription
controlled substances.’’ Id. The Show
Cause Order also alleged that
Respondent ‘‘routinely sold controlled
substance prescriptions and large
quantities of marijuana to known drug
peddlers.’’ Id.
More specifically, the Show Cause
Order alleged that Respondent had
distributed marijuana on a continuing
basis in quantities ranging from ‘‘small
user amounts’’ to as much as five
pounds. Id. The Show Cause Order also
alleged that Respondent had prescribed
Adderall, a schedule II controlled
substance, and hydrocodone, a schedule
III controlled substance, for a person
without ‘‘performing any tests or
formulat[ing] a diagnosis during the
initial visit,’’ and he had ‘‘continued to
authorize prescriptions for [these]
controlled substances without an
examination or further care.’’ Id.
Relatedly, the Show Cause Order
alleged that Respondent subsequently
‘‘received some of the hydrocodone
from the prescriptions [he] wrote for
this’’ person. Id.
Next, the Show Cause Order alleged
that Respondent had ‘‘prescribe[d]
controlled substances to a person [he]
knew was addicted to [them],’’ and that
Respondent also ‘‘knew [that] this
person was selling the filled
prescriptions to support [his]
addiction.’’ Id. The Show Cause Order
further alleged that Respondent had
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
engaged in a scheme to provide
controlled prescription drugs to drug
dealers. Id. According to the Show
Cause Order, the dealers’ runners would
go to Respondent’s residence to receive
the prescriptions; after the prescriptions
were filled, the dealer would provide
Respondent with half of the drugs and
sell the other half to drug abusers. Id.
Finally, the Show Cause Order alleged
that on May 10, 2006, law enforcement
officers executed a search warrant at
Respondent’s home during which they
found marijuana, pills which appeared
to be prescription controlled substances,
and assorted drug-related paraphernalia.
Id.
On January 12, 2007, DEA
investigators personally served the
Show Cause Order on Respondent.
Since that time, neither Respondent, nor
anyone purporting to represent him, has
responded. Because (1) more than thirty
days have passed since service of the
Show Cause Order, and (2) no request
for a hearing has been received, I
conclude that Respondent has waived
his right to a hearing. See 21 CFR
1301.43(d). I therefore enter this final
order without a hearing based on
relevant material contained in the
investigative file and make the
following findings.
Findings
Respondent is the holder of DEA
Certificate of Registration, BM5526009,
as a practitioner, which authorizes him
to dispense controlled substances in
schedules II through V. Respondent’s
registration was last renewed on
February 15, 2006, and expires on
January 31, 2009.
In July 1996, Respondent was
disciplined by the State Board of
Medical Examiners of South Carolina,
which found that he had written
prescriptions for Lortab 7.5
(hydrocodone), and Didrex
(benzphetamine),1 using the names of
other patients, which he then had filled
and diverted to his personal use.
Respondent admitted to the State’s
allegation. The Board fined him $7500,
issued a reprimand, and imposed
various conditions on his medical
license including random drug testing.
On October 17, 2000, however, the
Board removed the conditions.
According to the investigative file, the
Board’s conditions appeared to have
had only a limited impact on
Respondent. Beginning in the summer
of 1999, while the Board’s conditions
were still in effect, Respondent
purchased marijuana from a person who
1 Both drugs are schedule III controlled
substances. See 21 CFR 1308.13.
E:\FR\FM\03JYN1.SGM
03JYN1
]]>Agencies
[Federal Register Volume 72, Number 127 (Tuesday, July 3, 2007)]
[Notices]
[Page 36484]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12942]
[[Page 36484]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated March 19, 2007, and published in the Federal
Register on March 27, 2007, (72 FR 14297), Stepan Company, Natural
Products Dept., 100 W. Hunter Avenue, Maywood, New Jersey 07607, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cocaine (9041)............................. II
Ecgonine (9180)............................ II
------------------------------------------------------------------------
The company plans to manufacture in bulk for distribution to its
customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Stepan Company to manufacture the listed basic class of controlled
substance is consistent with the public interest at this time. DEA has
investigated Stepan Company to ensure that the company's registration
is consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with State and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic class of controlled substance listed.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-12942 Filed 7-2-07; 8:45 am]
BILLING CODE 4410-09-P
